PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Fox Chase Cancer Center

USPTO PatentsView assignee record - 10 granted patents across 13 technology areas, active 2015–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
10
Total patents granted
13
CPC technology areas
13.3
Avg claims per patent
-100%
5-year filing velocity

The verdict

Fox holds 10 US patents across 13 technology areas, rank #26,343 of 50,000 tracked assignees.

#26,343
of 50,000 US assignees by volume
Top 71%
by Innovation Score (29.0/100)
13.3
avg claims per patent
-100%
filing velocity, last 5 yrs

Portfolio overview

Fox Chase Cancer Center has been granted 10 US utility patents between 2015 and 2019, placing Fox Chase Cancer Center at rank #26,343 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Fox Chase Cancer Center is one of the more focused assignees in the PatentsView dataset. By volume, Fox sits between Fort Wayne Metals Research Products, Llc (10 patents, rank #26,339) and Fujita Health University (10 patents, rank #26,347) - the closest US assignees by grant volume. The composite Innovation Score of 29.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 10 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Fox Chase Cancer Center's 13.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Fox Chase Cancer Center against peers pursuing similar technology classes.

Who files at Fox's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Fox holds 10 patents at rank #26,343, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Fox's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

29 Top 71% higher than 29% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 2015201620172019 1
USPTO utility patent grants by year · 2015–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Fox Chase Cancer Center patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 4 40.0%
2016 4 40.0%
2017 1 10.0%
2019 1 10.0%

Which technologies does Fox Chase Cancer Center patent most?

Top 13 of 13 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#26,343

Across all tracked assignees

Innovation Score

29.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Fox Chase Cancer Center hold?
Fox Chase Cancer Center holds 10 US granted patents filed between 2015 and 2019, spanning 13 technology areas.
What is Fox Chase Cancer Center's Innovation Score?
Fox Chase Cancer Center has an Innovation Score of 29.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Fox Chase Cancer Center focus on?
Fox Chase Cancer Center's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 13 CPC subclasses total.
Is Fox Chase Cancer Center's patent filing rate increasing or decreasing?
Fox Chase Cancer Center's recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Fox Chase Cancer Center's patents?
Fox Chase Cancer Center's patents average 13.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Fox Chase Cancer Center patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Fox's 10 grants land it in the top 71% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Fox ranks #26,343 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.